



BAL PHARMA LIMITED

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1,
Palace Road, Bangalore - 560 052, India.

To
Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C/2, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051

To
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400001

Date: July 30, 2026

Symbol: BALPHARMA

Scrip Code: 524824

Sub: Intimation regarding Notice of Postal Ballot

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 –Opportunity to Shareholders pursuant to Corrigendum to Postal Ballot Notice

Dear Sir/Madam,

This is in continuation to our earlier intimations dated 09th July, 2026 regarding the Postal Ballot Notice and 23rd July, 2026 regarding the Corrigendum to the Postal Ballot Notice.

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and pursuant to the observations received from the Stock Exchange in relation to the Corrigendum issued to the Postal Ballot Notice dated 09th July, 2026, the Company hereby informs its Members that, in the interest of ensuring transparency and providing an additional opportunity to those Members who had exercised their voting rights prior to the issuance of the Corrigendum, the Company is providing a period of 48 (Forty-Eight) hours from the date and time of publication of this disclosure for submission of their comments, observations or objections, if any, in relation to the modifications contained in the Corrigendum.

Accordingly, the Members are requested to take note of the following:

Opportunity to Shareholders to Submit Comments

The Members are requested to take note of the modifications contained in the Corrigendum to the Postal Ballot Notice dated 23rd July, 2026. Any comments, observations or objections, if any, with respect to the modifications contained therein may be submitted within 48 (Forty-Eight) hours from the date and time of publication of this disclosure through any of the following email addresses:

Company E-mail ID: investors@balpharma.com

Scrutinizer's E-mail ID: parameshwar@vjkt.in



BAL PHARMA LIMITED

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1,
Palace Road, Bangalore - 560 052, India.

Further, as stated in Point No. 10 of the Corrigendum, Members who had already cast their votes prior to the issuance of the Corrigendum have been provided an opportunity to revise or modify their votes in accordance with the procedure specified therein.

The above opportunity is being provided to facilitate Members, particularly those who had exercised their voting rights before the issuance of the Corrigendum, to place on record their comments, observations or objections, if any, regarding the modifications introduced through the Corrigendum.

Members may further note that the remote e-voting facility shall continue to remain open until 5:00 P.M. (IST) on Saturday, August 08, 2026, in accordance with the Postal Ballot Notice read together with the Corrigendum.

The said intimation is also made available on the website of the Company at www.balpharma.com

Kindly take the above information on record.

Thanking You.

For Bal Pharma Ltd



Shreepada ML

Company Secretary and Compliance officer

ICSI M No : A66681